CRP and COVID-19: According to a local procedure established in their institution by the intensivist, internist and pneumologist patients were eligible to receive tocilizumab if they were admitted in ICU for a severe respiratory distress due to COVID-19 with at least 6 l/min of oxygen, symptom of COVID-19 > 7 days, the absence of therapeutic limitations, a high concentration of CRP and a low procalcitonin concentration in plasma.